Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

878.24 -18.76 (-2.09%)
Official Closing Price Updated: 7:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Dow 50,000: A Milestone for the History Books Amidst an AI Spending War ↗
Via Chartmill
Topics Artificial Intelligence Stocks
News headline image
HIMS Stock In Turmoil: Retail Bulls Bet On Rebound, Skeptics See Bloodbath After Compounded Weight-Loss Pill Halt ↗
Retail bulls pointed to similar price levels during high short interest in late 2024 and said ending compounded sales removes the risk of a costly legal fight. 
Via Stocktwits
Topics Intellectual Property Law Enforcement
News headline image
Eli Lilly Shares Surge on Weight-Loss Drug Momentum. Is It Time to Buy the Stock? ↗
It doesn't look too late to buy the stock. 
Via The Motley Fool
News headline image
Medicare Changes in 2026 Every Retiree Needs to Know: The Good, the Bad, and the Ugly ↗
Retirees should brace themselves for both positive and negative changes to Medicare this year. 
Via The Motley Fool
Topics Economy Government Retirement
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider. 
Via The Motley Fool
News headline image
3 Things Investors Need to Know About the Healthcare Sector in 2026 ↗
The most recent gold rush in weight loss drugs isn't done just yet. 
Via The Motley Fool
Topics Economy
News headline image
1 Brilliant Vanguard Index Fund to Buy Before It Soars 120%, According to a Wall Street Analyst ↗
Tom Lee says the S&P 500 (a benchmark for the U.S. stock market) can hit 15,000 by 2030. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗
Via MarketBeat
News headline image
Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition
Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83... 
Via MarketMinute
Topics Earnings Economy
News headline image
AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months
In a breakthrough that many are calling the "Penicillin Moment" of the 21st century, researchers at the Massachusetts Institute of Technology, led by bioengineering pioneer James Collins, have... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,... 
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore ↗
The market for obesity drugs may soon reach almost $100 billion. 
Via The Motley Fool
News headline image
The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market
The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
What Does the Market Think About Eli Lilly and Co? ↗
 
Via Benzinga
News headline image
Why Shares of Novo Nordisk Stock Collapsed This Week ↗
The drugmaker is facing pricing pressures on its weight loss medications. 
Via The Motley Fool
News headline image
The Trillion-Dollar Divergence: Eli Lilly Hits Milestone While Novo Nordisk Faces 'Supply Chain Reset'
The global race for obesity market dominance reached a historic turning point this week as Eli Lilly and Company (NYSE: LLY) officially crossed the $1 trillion market capitalization threshold,... 
Via MarketMinute
Topics Economy
News headline image
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance
As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade... 
Via Finterra
Topics Economy Government Intellectual Property
News headline image
Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse
As of February 6, 2026, Biogen Inc. (NASDAQ: BIIB) stands at a critical crossroads in its nearly 50-year history. Once the undisputed titan of the Multiple Sclerosis (MS) market, the Cambridge-based... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
The $180 Billion Gamble: Alphabet’s High-Stakes AI Transformation in 2026
Date: February 6, 2026 Introduction Alphabet Inc. (NASDAQ: GOOGL / GOOG) currently stands at the most consequential crossroads in its 28-year history. Once the undisputed king of the information age,... 
Via Finterra
Topics Artificial Intelligence Economy Initial Public Offering
These S&P500 stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
News headline image
Walmart Just Became the Newest Member of the Trillion-Dollar Club, and These 2 Non-AI Stocks May Be Next -- but There's a Catch ↗
Two standout companies from the same sector (no, not technology) have a clear path to follow in Walmart's footsteps. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
News headline image
Eli Lilly Stock Has Over 20% Upside, Analysts Say: Retail Seeks Pharma 'Safe Haven' As FDA Targets GLP-1 Copycats ↗
The stock’s rise followed FDA Commissioner Marty Makary's warning against companies marketing illegal copycat drugs. 
Via Stocktwits
Topics Fraud Law Enforcement
News headline image
Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. ↗
There's another fight brewing around GLP-1 drugs -- this time on the delivery side. 
Via The Motley Fool
News headline image
The Great Rebalancing: Why Investors are Fleeing Big Tech for the 'Safety' of Utilities and Healthcare
As of early February 2026, the long-standing dominance of high-growth technology and artificial intelligence (AI) stocks has hit a significant wall, triggering a massive "Great Rebalancing" across the... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most ↗
Via MarketBeat
News headline image
Trade War 2.0: 25% Tariffs on Chips, Cars, and Medicine Reshape the Global Supply Chain
The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a... 
Via MarketMinute
Topics Earnings Economy
News headline image
ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY
From Scott+Scott Attorneys at Law LLP
Via Business Wire
News headline image
Eli Lilly Just Delivered Fantastic News to Shareholders ↗
The stock price has climbed in the triple digits over three years. 
Via The Motley Fool
Topics Government
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.